Ocular Therapeutix/ US67576A1007 /
| 2024-05-16 9:59:48 PM | Chg. -0.01 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 6.29USD | -0.08% | 119,717 Turnover: 734,871 |
-Bid Size: - | -Ask Size: - | 6.36 | 5.94 |
GlobeNewswire
05-07
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
05-01
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
GlobeNewswire
04-18
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
GlobeNewswire
04-09
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice Pre...
GlobeNewswire
04-06
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...
GlobeNewswire
03-26
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract a...
GlobeNewswire
03-05
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
GlobeNewswire
02-22
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed...
GlobeNewswire
02-13
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ ...
GlobeNewswire
02-08
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Promptin...
GlobeNewswire
01-25
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal C...
